Two biologic medicines for tough Crohn's disease
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study compares two biologic medicines, ustekinumab and upadacitinib, to see which works better for people with Crohn's disease that hasn't improved with other treatments. The goal is to reduce inflammation and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had Crohn's disease for at least 3 months.
- You have at least one ulcer in your intestine seen during a colonoscopy.
- You have tried and not improved on, or couldn't tolerate, an anti-TNF medicine like infliximab or adalimumab.
- You are not currently taking certain other Crohn's drugs, or you can stop them before the study starts.
- You have no active infections, including tuberculosis (TB), and you meet the TB screening requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
Hear when a new Crohn's Disease Aggravated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.